Sintilimab improves survival in advanced non-metastatic nasopharyngeal carcinoma
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
1. Fewer patients in the hyperfractionation group reported grade 3 or worse late radiation-induced complications compared to the standard fractionation ...
Click to read this study in JAMA Network Open.
Click to read this study in JAMA Oncology.
Click to read this study in the Journal of Clinical Oncology.
1. Patients with low-risk nasopharyngeal carcinoma did not have significantly different disease-free survival rates whether they received radiotherapy alone or ...
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in The Lancet Oncology.
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and capecitabine group was 83.5% versus 68.9% in ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.